GH Stack

Overview

The GH Stack is the popular name for the combination of CJC-1295 (without DAC) and Ipamorelin — two synthetic peptides that activate complementary but distinct receptor pathways governing growth hormone (GH) release from the anterior pituitary. CJC-1295 is a GHRH analog that activates the GHRH receptor (GHRHR), while Ipamorelin is a selective ghrelin receptor agonist that activates the growth hormone secretagogue receptor type 1a (GHS-R1a). When both pathways are stimulated simultaneously, the intracellular signaling cascades interact synergistically — producing GH output significantly greater than either compound achieves independently, while maintaining a physiologically relevant pulsatile release pattern. Ipamorelin's defining selectivity — robust GH release with no significant cortisol, ACTH, or prolactin elevation — makes it the preferred GHRP partner for CJC-1295. The GH Stack is one of the most researched and widely studied growth hormone secretagogue combinations in peptide research.

How They Work Together

1. CJC-1295 Role [1] — CJC-1295 without DAC acts as the sustained GHRH signal, binding to GHRH receptors on pituitary somatotrophs and activating cAMP-dependent GH gene transcription and secretion. It primes the somatotroph and provides the biochemical foundation for GH synthesis. Its approximately 30-minute half-life produces discrete GH pulses that mirror physiological GHRH pulsatility.
2. Ipamorelin Role [2] — Ipamorelin acts through the separate GHS-R1a (ghrelin receptor) pathway on the same pituitary somatotrophs, triggering rapid calcium-mediated GH secretion. It produces an earlier onset, more acute GH pulse that complements CJC-1295's sustained receptor engagement. Critically, it does this without elevating cortisol, ACTH, prolactin, FSH, LH, or TSH.
3. The Synergy [3] — The GHRH + GHRP synergy is well documented in research. Simultaneous activation of both receptor pathways produces supraadditive GH release — greater than the arithmetic sum of each compound's individual effect. This occurs because the cAMP pathway (CJC-1295/GHRHR) and the calcium/PKC pathway (Ipamorelin/GHS-R1a) converge and amplify each other at the secretory machinery of the somatotroph. The result is amplified pulsatile GH output in a pattern that closely mirrors natural GH secretion.

Key Research Areas

1. GHRH + GHRP Synergy [3] — Research established that simultaneous stimulation of both receptor pathways produces a synergistic GH response. CJC-1295 studies in humans demonstrated 2–10 fold GH increases above baseline; the addition of Ipamorelin amplifies this further through complementary receptor engagement.
2. Body Composition [1] — Elevated GH and downstream IGF-1 promote lean muscle synthesis, fat metabolism (particularly visceral fat), improved body composition, and enhanced tissue repair — the primary research areas for the GH Stack.
3. Sleep Quality [1] — Growth hormone is predominantly secreted during slow-wave sleep. GH Stack protocols administered before sleep are studied for their potential to enhance slow-wave sleep quality and the associated restorative processes.
4. Recovery and Tissue Repair [1] — Elevated GH and IGF-1 levels support faster recovery from exercise-induced muscle damage and injury through enhanced protein synthesis and cellular repair mechanisms.
5. Anti-Aging and Sarcopenia Prevention [1] — GH axis activity declines significantly with age. The GH Stack is studied as a means of supporting GH axis function in older adults to counteract age-related muscle loss, fat accumulation, and metabolic decline.

Observed Benefits in Research

1. Synergistic GH amplification beyond individual compound effects
2. Physiologically relevant pulsatile GH release pattern
3. Elevated IGF-1 supporting anabolic and metabolic processes
4. No significant cortisol or ACTH elevation (Ipamorelin selectivity)
5. Potential improvements in body composition, lean mass, and fat metabolism
6. Enhanced sleep quality through GH-mediated slow-wave sleep support
7. Accelerated recovery from exercise and tissue repair

Research Limitations

(1) Most evidence is from preclinical models and small human studies — large-scale RCTs are lacking. (2) Long-term effects of sustained GH stimulation via dual-pathway activation are not fully established. (3) Theoretical risks include insulin resistance, receptor desensitization with prolonged use, and theoretical mitogenic effects from chronic IGF-1 elevation. (4) Neither CJC-1295 nor Ipamorelin is FDA approved. (5) Both compounds are prohibited in competitive sport by WADA. (6) Optimal dosing ratios, timing, and cycle lengths for the combination remain under investigation.

Individual Peptide Profiles

References

1. Spartan Peptides. CJC-1295 and Ipamorelin: The Research-Backed Growth Hormone Peptide Blend. 2026. https://spartanpeptides.com/blog/cjc-1295-ipamorelin-complete-2026-research-guide/
2. PubMed. Ipamorelin, the first selective growth hormone secretagogue. 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/
3. PubMed. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/